Speak directly to the analyst to clarify any post sales queries you may have.
Biologics contract development and manufacturing organizations (CDMOs) comprise companies specialized in developing, producing, and manufacturing biopharmaceutical products derived from living organisms. These organizations offer end-to-end services to pharmaceutical and biotech companies that require assistance bringing their innovative biological-based products to market. The development of the biologics CDMO market is influenced by several factors, such as an increase in demand for biopharmaceuticals due to the increasing prevalence of chronic conditions and aging people. Additionally, the advancement in bioprocessing technologies has enabled efficient large-scale production with reduced costs. However, stringent regulatory requirements imposed by authorities for product quality control throughout the manufacturing process may hamper the market demand. New opportunities are emerging within the industry due to advancements in personalized medicine and targeted therapy approaches requiring novel biological treatments. A surge in interest in next-generation biotherapeutics such as multi-specifics or bispecific antibodies, antibody-drug conjugates (ADCs), and gene editing technologies is expected to create a lucrative market opportunity in the forecasted period.
Regional Insights
The Americas has a significant landscape in the biologics contract development and manufacturing market due to several well-established CDMOs and its robust regulatory environment governed by the FDA. In the context of biologics contract development and manufacturing organizations (CDMOs), Europe holds immense potential due to significant investment in research and development (R&D). With well-funded institutions and universities scattered across the continent, Europe has established itself as a global center for scientific innovation. The growth of the APAC region is driven by rising healthcare expenditure, increasing investments in the pharmaceutical and biotechnology sectors, favorable government policies to promote research and development (R&D), and a burgeoning demand for advanced therapeutics driven by an increasing prevalence of chronic conditions.FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Biologics Contract Development & Manufacturing Organization Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Biologics Contract Development & Manufacturing Organization Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.Key Company Profiles
The report delves into recent significant developments in the Biologics Contract Development & Manufacturing Organization Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Abzena Ltd., Aenova Holding GmbH, AGC Biologics GmbH, Avid Bioservices, Inc., Binex Co. Limited, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Emergent BioSolutions, Inc., Fujifilm Holdings Corporation, Icon PLC, JSR Life Sciences, LLC, Lonza Group AG, Parexel International Corporation, ProBioGen AG, Recipharm AB, Rentschler Biopharma SE, Samsung Biologics, Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Inc., Toyobo Co., Ltd., and WuXi Biologics Inc.Market Segmentation & Coverage
This research report categorizes the Biologics Contract Development & Manufacturing Organization Market to forecast the revenues and analyze trends in each of the following sub-markets:- Type
- Mammalian
- Non-mammalian
- Product Type
- Biologics
- Antisense & Molecular Therapy
- Monoclonal
- Recombinant Proteins
- Vaccines
- Biosimilars
- Biologics
- Disease Indication
- Cardiovascular Disorders
- Hematological Disorders
- Immunological Disorders
- Oncology
- Service Type
- Cell Line Development
- Mammalian
- Microbial
- Process Development
- Downstream
- Impurity, Isolation, & Identification
- Pharmaceutical Analysis
- Physicochemical Characterization
- Upstream
- Mammalian
- Microbial
- Downstream
- Cell Line Development
- End-User
- Biopharmaceutical Companies
- Research Laboratories
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as
- What is the market size and forecast of the Biologics Contract Development & Manufacturing Organization Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Biologics Contract Development & Manufacturing Organization Market?
- What are the technology trends and regulatory frameworks in the Biologics Contract Development & Manufacturing Organization Market?
- What is the market share of the leading vendors in the Biologics Contract Development & Manufacturing Organization Market?
- Which modes and strategic moves are suitable for entering the Biologics Contract Development & Manufacturing Organization Market?
Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.
This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.
Table of Contents
Companies Mentioned
- AbbVie, Inc.
- Abzena Ltd.
- Aenova Holding GmbH
- AGC Biologics GmbH
- Avid Bioservices, Inc.
- Binex Co. Limited
- Boehringer Ingelheim International GmbH
- Cambrex Corporation
- Catalent, Inc.
- Emergent BioSolutions, Inc.
- Fujifilm Holdings Corporation
- Icon PLC
- JSR Life Sciences, LLC
- Lonza Group AG
- Parexel International Corporation
- ProBioGen AG
- Recipharm AB
- Rentschler Biopharma SE
- Samsung Biologics
- Takeda Pharmaceutical Company Limited
- Thermo Fisher Scientific, Inc.
- Toyobo Co., Ltd.
- WuXi Biologics Inc.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 190 |
Published | March 2024 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 10.59 Billion |
Forecasted Market Value ( USD | $ 16.35 Billion |
Compound Annual Growth Rate | 7.4% |
Regions Covered | Global |
No. of Companies Mentioned | 23 |